It’s often said that success doesn’t happen overnight. Consider Durham-based anti-infectives startup ValanBio Therapeutics. The journey that led to the development of its new synthetic antibiotic technology – LPC-233 – began about 40 years ago. And it isn’t over yet.
Read More
Locus Biosciences has inked nearly $1 billion in deals to develop its gene-editing and bacteriophage technology that could combat antibiotic resistance and which targets specific bad bacteria, leaving good bacteria unharmed. Here’s the story, exclusively for TechWire readers.
Read More
Working with this polymer created by IBM Research, scientists from A*STAR’s Institute of Bioengineering and Nanotechnology (IBN) discovered that these polymers showed no onset of resistance after many sub-lethal treatments, due to a unique mechanism that included membrane translocation followed by precipitation of cytosolic biomacromolecules.
Read MoreDrug-resistant superbugs are as big a threat to the world as climate change or wars, Britain’s Health Secretary Matt Hancock warned during a speech at Davos.
Read More
Research at NC State suggests ants may provide a future source of new antibiotic agents.
Read More
Locus Biosciences, expanding on the heels of an acquisition, is taking new larger digs at Keystone Technology Park.
Read More
Researchers from North Carolina State University have synthesized an analog of a small molecule that is effective against drug-resistant bacteria
Read More
